Document Detail


Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
MedLine Citation:
PMID:  8641009     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Thrombolysis to normal flow in patients with acute myocardial infarction preserves left ventricular function and decreases mortality. Failure of early reperfusion, reocclusion, or residual thrombus may be due to concurrent activation of the platelet-coagulation system. Thus, we hypothesized that the best concomitant antithrombotic therapy (recombinant [r]-hirudin, heparin, or aspirin) will maximally accelerate thrombolysis by r-tissue-type plasminogen activator (rTPA) and reduce residual thrombus. METHODS AND RESULTS: Occlusive thrombi were formed in the carotid arteries of 29 pigs (by balloon dilatation followed by endarterectomy at the site of injury-induced vasospasm) and matured for 30 minutes before rTPA was started, with or without antithrombotic therapy. Thrombolysis was assessed with the use of angiography and measurement of residual thrombus. Pigs were allocated to one of five treatments: placebo, rTPA, rTPA plus r-hirudin, rTPA plus heparin, or rTPA plus intravenous aspirin. No placebo-treated pig reperfused. Two of six animals treated with rTPA alone reperfused compared with seven of seven animals treated with rTPA plus r-hirudin (reperfusion time, 33 +/- 10 minutes), six of seven animals treated with rTPA plus heparin (reperfusion time, 110 +/- 31 minutes), and two of six animals with rTPA plus aspirin. The activated partial thromboplastin time was prolonged in only the rTPA plus r-hirudin group (25 +/- 0.1 times baseline) and the rTPA plus heparin group (5.3 +/- 0.2 times baseline). Residual 111In-platelet and 125I-fibrin(ogen) depositions were lower in the heparin-treated group and lowest in the r-hirudin-treated group (heparin versus hirudin, respectively; incidence of residual macroscopic thrombus was six of six animals versus two of seven [P = .01]; 125I-fibrin(ogen), 170 +/- 76 versus 48 +/- 6 x 10(6) molecules/cm2 [P = .02]; 111In-platelets, 47 +/- 15 versus 13 +/- 2 x 10(6)/cm2, P = .10). No pigs developed spontaneous bleeding. CONCLUSIONS: Thrombin inhibition with heparin or r-hirudin significantly accelerated thrombolysis of occlusive platelet-rich thrombosis, but only the best antithrombotic therapy (r-hirudin) eliminated or nearly eliminated residual thrombus.
Authors:
J S Mruk; P Zoldhelyi; M W Webster; M Heras; D E Grill; D R Holmes; V Fuster; J H Chesebro
Related Documents :
10709819 - Reduction of blood loss and transfusion requirements after coronary artery bypass graft...
12588269 - Bivalirudin and provisional glycoprotein iib/iiia blockade compared with heparin and pl...
7758189 - Aspirin enhances the benefits of late reperfusion on infarct shape. a possible mechanis...
21923439 - Comparison of rate control versus rhythm control for management of atrial fibrillation ...
12757769 - Oral anticoagulation after myocardial infarction.
9475539 - Heparin and nonanticoagulant heparin preserve regional myocardial contractility after i...
17283249 - Beta1 integrins modulate beta-adrenergic receptor-stimulated cardiac myocyte apoptosis ...
16606819 - Clopidogrel to treat patients with non-st-segment elevation acute coronary syndromes af...
20048269 - Systematic review: prediction of perioperative cardiac complications and mortality by t...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Circulation     Volume:  93     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1996 Feb 
Date Detail:
Created Date:  1996-07-15     Completed Date:  1996-07-15     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  792-9     Citation Subset:  AIM; IM    
Affiliation:
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Aspirin / administration & dosage,  therapeutic use*
Blood Platelets / drug effects,  pathology
Carotid Arteries / drug effects,  metabolism,  pathology
Drug Therapy, Combination
Fibrin / metabolism
Fibrinolytic Agents / administration & dosage,  therapeutic use*
Hemostasis
Heparin / administration & dosage,  therapeutic use*
Hirudin Therapy*
Hirudins / administration & dosage
Humans
Recombinant Proteins / administration & dosage,  therapeutic use
Swine
Thrombosis / drug therapy*,  pathology
Time Factors
Tissue Plasminogen Activator / administration & dosage,  therapeutic use
Grant Support
ID/Acronym/Agency:
HL-07111/14T/HL/NHLBI NIH HHS; HL-39959/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Hirudins; 0/Recombinant Proteins; 50-78-2/Aspirin; 9001-31-4/Fibrin; 9005-49-6/Heparin; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioni...
Next Document:  Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combin...